An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.
The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.
Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.
Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.
NEW YORK – Quest Diagnostics raised its full-year 2026 revenue and EPS guidance on Thursday as the company saw solid Q2 growth across its business. The firm said it now expects full-year net revenue ...
The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.
The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.
NEW YORK – Based on data generated in the National Lung Screening Trial (NLST) cohort, cancer testing firm Mercy BioAnalytics believes its lung cancer early detection assay can identify cancers missed ...
The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results